CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer

Inclusion Criteria

• •Histologically confirmed adenocarcinoma of the prostate, previously untreated
• •Potential candidate for radical prostatectomy on the basis of the patient's general medical condition, performance status, and life expectancy
• •Potential candidate for NHT prior to prostatectomy, including high or intermediate risk of recurrence, based on an estimated risk of biochemical recurrence: High risk category: PSA \>20 or Gleason score 8 or cT2c/cT3 OR Intermediate risk category: PSA \>10 and d20 or Gleason score 7 or cT2b
• •No evidence of metastatic disease by physical examination, bone scan, and computed tomography, or MRI, of the abdomen and pelvis
• •Age \> 18 years
• •ECOG performance status 0-1
• •Adequate bone marrow, hepatic, and renal function determined within 2 weeks prior to starting therapy
• •Availability of prostatectomy specimen for histological analysis at the Armed Forces Institute of Pathology